FDA Inspection 1051173 — Samsung Bioepis Co., Ltd
The FDA completed an inspection of Samsung Bioepis Co., Ltd on Apr 6, 2018 in Suwon. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 6, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Suwon (Korea (the Republic of))
Additional Details
Sponsor, Contract Research Organization